Pharmacologic Targeting of TFIIH Suppresses KRAS-Mutant Pancreatic Ductal Adenocarcinoma and Synergizes with TRAIL
Russell Moser(Cape Town HVTN Immunology Laboratory / Hutchinson Centre Research Institute of South Africa), Christopher J. Kemp(Fred Hutch Cancer Center), Eduardo Méndez(University of Washington Medical Center), Craig Dorrell(Oregon Health & Science University), Haiyong Han(Translational Genomics Research Institute), James Annis(Rosetta Stone (United States)), Olga Nikolova(Oregon Health & Science University), Kay E. Gurley(Fred Hutch Cancer Center), Kim Moran‐Jones(NHS Greater Glasgow and Clyde), Carla Grandori(Precision for Medicine (United States)), Daniel D. Von Hoff(Translational Genomics Research Institute), Rosalie C. Sears(Oregon Health & Science University), Andrew V. Biankin(University of Glasgow), Calvin J. Kuo(Stratford University), Cliff Whatcott(Translational Genomics Research Institute)
Cited by 11
Related Papers
Signatures of mutational processes in human cancer
|Nature|2013|10.1k
Increased Survival in Pancreatic Cancer with nab-Paclitaxel plus Gemcitabine
|New England Journal of Medicine|2013|6.6k
Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial.
|Journal of Clinical Oncology|1997|5.9k
In vitro expansion of single Lgr5+ liver stem cells induced by Wnt-driven regeneration
|Nature|2013|1.6k
Multiple Ras-dependent phosphorylation pathways regulate Myc protein stability
|Genes & Development|2000|1.4k